His research interests have focused on the prevention of cardiovascular disease with a special interest in lipids and diabetes. He has investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control, and the risks/benefits of aspirin therapy. These have influenced AHA/ACC and ESC guidelines. His work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. He continue to investigate the role of lipids, lipoproteins, diabetes, inflammation and thrombosis and coronary events. He has received research grants including from the British Heart Foundation, the Wellcome Trust, Pfizer, Amgen, Sanofi, MSD, and the European Atherosclerosis Society (EAS). Currently he leads the EAS Familial Hypercholesterolaemia (FH) Studies collaboration which is the first global registry for FH and now includes approximately sixty countries, and is in the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.